3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other solid neoplasm
1
Conditions
Carcinoma, Non-Small-Cell Lung
63
Carcinoma, Hepatocellular
55
Lung Neoplasms
32
Breast Neoplasms
29
Small Cell Lung Carcinoma
23
Neoplasms
21
Triple Negative Breast Neoplasms
18
Neoplasm Metastasis
17
Urinary Bladder Neoplasms
15
Carcinoma, Transitional Cell
15
Melanoma
14
Colorectal Neoplasms
14
Glioblastoma
10
Prostatic Neoplasms
9
Ovarian Neoplasms
9
Head and Neck Neoplasms
9
Recurrence
8
Liver Neoplasms
8
Endometrial Neoplasms
8
Carcinoma, Renal Cell
8
Mesothelioma, Malignant
7
Uterine Cervical Neoplasms
6
Sarcoma
6
Stomach Neoplasms
5
Squamous Cell Carcinoma of Head and Neck
5
Rectal Neoplasms
5
Kidney Neoplasms
5
Gastrointestinal Neoplasms
5
Carcinoma, Squamous Cell
5
Pancreatic Neoplasms
4
Interventions
Cyclophosphamide
3
fludarabine
2
Radiotherapy
2
Interleukin-2
2
tislelizumab
1
pembrolizumab
1
pazopanib
1
patritumab deruxtecan
1
palbociclib
1
niraparib
1
neotil
1
lenvatinib
1
atezolizumab
1
Yoga
1
X-Rays
1
Watchful Waiting
1
Tomography, X-Ray Computed
1
Tiragolumab
1
Surveys and Questionnaires
1
Radiation
1
Positron-Emission Tomography
1
Nivolumab
1
Magnetic Resonance Imaging
1
Lacteol
1
Ipilimumab
1
High-Throughput Nucleotide Sequencing
1
Fluorodeoxyglucose F18
1
Data Collection
1
Cryosurgery
1
Celecoxib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Solid Tumor, Adult
×
atezolizumab
×
Clear all
NCT06003621
2024-11-15
MoST-TAP
Omico
Phase 2
Recruiting
96 enrolled